Literature DB >> 28295992

Liver transplantation versus liver resection for hepatocellular carcinoma in intention to treat: An attempt to perform an ideal meta-analysis.

Benjamin Menahem1,2, Jean Lubrano1,2, Christophe Duvoux3, Andrea Mulliri1, Arnaud Alves1, Charlotte Costentin3, Ariane Mallat3, Guy Launoy2, Alexis Laurent4,5.   

Abstract

This meta-analysis compared the effects of liver transplantation (LT) and liver resection (LR) on overall survival (OS) and disease-free survival (DFS) in patients with hepatocellular carcinoma (HCC) small transplantable HCC or within Milan criteria. Articles comparing LR with LT for HCC, based on Milan criteria or small size, published up to June 2015 were selected, and a meta-analysis was performed. No randomized controlled trial has been published to date comparing survival outcomes in patients with HCC who underwent LR and LT. Nine studies were identified, including 570 patients who underwent LR and 861 who underwent LT. For HCC within the Milan criteria, the 1-year OS rates following LR and LT were 84.5% (473/560) and 84.4% (710/841), respectively (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.71-1.33; P = 0.8), and the 5-year OS rates were 47.9% (273/570) and 59.3% (509/858), respectively (OR, 0.60; 95% CI, 0.35-1.02; P = 0.06). One-year DFS rates were similar (OR, 1.00; 95% CI, 0.39-2.61; P = 1.00), whereas the 3-year DFS rate was significantly lower in the LR group (54.4%, 210/386) than in the LT group (74.2%, 317/427; OR, 0.24; 95% CI, 0.07-0.80; P = 0.02), and the 5-year DFS rate was significantly lower for LR than LT (OR, 0.18; 95% CI, 0.06-0.53; P < 0.01). For small HCCs, the 5-year OS rate was significantly lower for patients who underwent LR than LT (OR, 0.30; 95% CI, 0.19-0.48; P < 0.001). In conclusion, relative to LR, LT in patients with HCC meeting the Milan criteria had no benefits before 10 years for OS. For DFS, the benefit is obtained after 3 years. Liver Transplantation 23 836-844 2017 AASLD.
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28295992     DOI: 10.1002/lt.24758

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  28 in total

1.  Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis.

Authors:  Richard H Lewis; Evan S Glazer; David M Bittenbinder; Thomas O'Brien; Jeremiah L Deneve; David Shibata; Stephen W Behrman; Jason M Vanatta; Sanjaya K Satapathy; Paxton V Dickson
Journal:  J Gastrointest Cancer       Date:  2019-12

Review 2.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

3.  Trends in the Mortality of Hepatocellular Carcinoma in the United States.

Authors:  Eliza W Beal; Dmitry Tumin; Ali Kabir; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Kenneth Washburn; Sylvester Black; Carl M Schmidt; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2017-08-07       Impact factor: 3.452

4.  Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA.

Authors:  Eliza W Beal; Dmitry Tumin; Ali Kabir; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Kenneth Washburn; Sylvester Black; Carl M Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

5.  Race and Gender Disparity in the Surgical Management of Hepatocellular Cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Program Registry.

Authors:  Michael Darden; Geoffrey Parker; Dominique Monlezun; Edward Anderson; Joseph F Buell
Journal:  World J Surg       Date:  2021-04-23       Impact factor: 3.352

Review 6.  Biological functions and clinical applications of exosomal non-coding RNAs in hepatocellular carcinoma.

Authors:  Changbiao Li; Xiao Xu
Journal:  Cell Mol Life Sci       Date:  2019-07-12       Impact factor: 9.261

Review 7.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

Review 8.  [Treatment of hepatocellular carcinoma in the cirrhotic and non-cirrhotic liver].

Authors:  M Schmelzle; F Krenzien; W Schöning; J Pratschke
Journal:  Chirurg       Date:  2018-11       Impact factor: 0.955

9.  Genomic Landscape of HCC.

Authors:  Adeniji Nia; Renumathy Dhanasekaran
Journal:  Curr Hepatol Rep       Date:  2020-11-10

Review 10.  Integrative Concepts for Liver Surgery.

Authors:  Stefan Heinrich; Felix Watzka; Hauke Lang
Journal:  Visc Med       Date:  2020-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.